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Abstract 
Introduction  
The COVID-19 pandemic poses a high risk to older people. The aim of this paper is to provide a rapid 
overview of the COVID-19 literature, with a specific focus on older adults. We frame our findings 
within an overview of the disease and have also evaluated the inclusion of older people within 
forthcoming clinical trials. 
Methods  
We searched PubMed and bioRxiv/medRxiv to identify English language papers describing the 
testing, treatment and prognosis of COVID-19. PubMed and bioRxiv/medRxiv searches took place on 
20th and 24th March 2020, respectively. 
Results 
Screening of over 1,100 peer-reviewed and pre-print papers yielded n=22 on COVID-19 testing, n=15 
on treatment and n=13 on prognosis. Viral-PCR and serology are the mainstays of testing but a 
positive diagnosis may be increasingly supported by radiological findings. The current evidence for 
the effectiveness of antiviral, corticosteroid and immunotherapies is inconclusive, although trial data 
are largely based on younger people. In addition to age, male gender and comorbidities, specific 
laboratory and radiology findings are important prognostic factors. Evidence suggests social 
distancing policies could have important negative consequences, particularly if in place for an 
extended period.  
Conclusion 
Given the established association between increasing age and poor prognosis in COVID-19, we 
anticipate that this rapid review of the current and emergent evidence might form a basis on which 
future work can be established.  Exclusion of older people, particularly those with comorbidities, 
from clinical trials is well recognised and is potentially being perpetuated in the field of current 
COVID-19 research.   
 
Key Points  
 
 
• Older patients have a higher mortality and may present atypically with delirium, postural 
instability or diarrhoea, and without fever. 
• Given the lack of sensitivity of individual tests, information from different testing modalities 
can be incorporated to support diagnosis. 
• In addition to age, male gender and presence of comorbidities, specific laboratory and 
radiology findings are important prognostic factors. 
• Social distancing and isolation may have negative consequences for older people, unrelated 
to COVID-19. 
• Older patients are relatively excluded from clinical trials relating to COVID-19.  
 
 
Introduction 
In January 2020, a cluster of pneumonia cases in Wuhan City, Hubei province, China were identified 
as having been caused by the SARS-CoV-2 virus, leading to the disease now termed COVID-19. The 
subsequent global transmission led to the outbreak being classified as a pandemic by the World 
Health Organisation (WHO) on 11th March 2020. In the United Kingdom (UK), public health measures 
to control the spread of disease have, to date, included directives to self-isolate, socially distance, 
and so called ‘lockdown’ whereby activity and movement within a community is contained or 
limited. 
Older adults, and those with comorbidities, are at particular risk of having severe infection [1] and 
are at higher risk of dying as a result of the disease [2-4]. In one of the largest case series so far 
published, of 72,314 cases reported by the Chinese Centre for Disease Control and Prevention, case 
fatality was 8.0% (312 of 3918) in patients 70-79 years old and 14.8% in patients aged ≥80 years (208 
of 1408). Older adults appear to be more susceptible to the virus; 75% of known infections are in 
persons aged 50 and over.  
In the UK and Europe, we are seeing an increasing number of cumulative cases and a rising trend in 
the daily number of confirmed COVID-19 cases. As such we have recognised an urgent need to 
provide clinicians, who may be less familiar with geriatric medicine, with a comprehensive overview 
of COVID-19 infection in older people. The overarching aim of this paper is to provide a rapid semi-
systematic review of both peer-reviewed and pre-print evidence relating to COVID-19 testing, drug 
treatment and prognosis, as of late March 2020. We have presented these findings within a broader 
context discussing clinical presentation, supportive care strategies and social distancing in older 
people.  Our findings, coupled with evaluation of the landscape of current and future clinical trials, 
have highlighted areas of priority for future research directed toward COVID-19 infection in older 
people.  
Clinical overview of COVID-19 
The current WHO suspected case definition is shown in Box 1 [5]. Clinical manifestations are 
summarised in Box 2. Cohort studies of patients with mild and moderate disease showed that fever 
was the most common symptom in 82-87% of cases, followed by cough in 36-66% [6]. This reflects 
findings from a meta-analysis of cases in China [7] where, of note, fever was more common during 
admission that at presentation [8]. In the RADAR COVID-19 study, in patients in a community setting 
with symptoms that warranted testing, anosmia was present in 59% who tested positive [9]. Other 
 
 
clinical features include headache, rhinorrhoea, gastrointestinal symptoms, sore throat and fatigue. 
Cardiac complications are described including myocarditis [10], pericardial effusion on imaging [11] 
and arrhythmia [12] which is seen more commonly in those with greater disease severity [13]. 
Patients with severe infection can develop a pro-inflammatory cytokine release syndrome which can 
lead to rapid deterioration and death [14]. The majority of studies to date have notably reported 
symptoms occurring in patients with proven infection in hospitals.  
Early reports substantiate that older people with COVID-19 will likely present atypically [15]; 
experience in France suggests that this group may initially present with delirium, postural instability 
or diarrhoea, rather than with typical respiratory symptoms and fever [16]. With  COVID-19  being 
detected in older people who are in hospital for other illnesses, such as following a fall [16], it 
remains to be determined as to what extent these index events are precipitated by COVID-19 
infection versus COVID-19 being found incidentally. Atypical presentations omitted from public 
health campaigns, such as diarrhoea, showed a pooled incidence rate of 9.2% [17]. Limited data are 
available on rates of delirium in COVID-19 infection, although the risk has been identified by the 
WHO and the British Geriatrics Society (BGS) who have produced specific guidelines to support 
delirium management in this context (Box 3) [18].  
Typical findings on blood tests are lymphopenia and elevated C reactive protein (CRP) [19]. In 
moderate-to-severe cases increased procalcitonin levels have been observed [20]. Consistent with 
the aforementioned cardiac complications, severe cases often see raised levels of troponin I, D-
dimer and lactate dehydrogenase [3, 12, 19, 21].  Chest radiograph (CXR) features are foci of ill-
defined opacification with bibasal predilection, evolving to consolidation [17, 19]. On chest 
computerised tomography (CT), chest typical findings include lower lobe and peripheral 
predominance with multiple, bilateral foci of ground glass opacity [7, 17, 22] with or without crazy-
paving, peripheral consolidation, air bronchograms and reverse halo or perilobular pattern [23]. 
Importantly, radiological changes may be absent in early disease (56% of 36 patients scanned 
between 0-2 days of symptom onset had a normal CT) [24] and minimal in mild disease (18% of 877 
patients with non-severe disease clinically had no radiological abnormality.  In severe cases, only 3% 
had no radiological signs. In light of this, COVID-19 cannot necessarily be ruled out on the basis of 
a normal CT whilst there is some evidence to suggest that the negative predictive value of CT is 
higher when symptom duration is >1 week [23, 25, 26].   
The main complication of COVID-19 is acute respiratory distress syndrome (ARDS).  This is reported 
to occur in between 15% [7] and 23% [17] of cases. Other complications include respiratory failure 
 
 
[27], acute kidney injury [27, 28], and liver dysfunction [28]. Described causes of death include 
pneumonia, multi-organ failure, and severe acute respiratory syndrome [3, 19]. 
There is a striking paucity of peer reviewed evidence that examines the specific characteristics of 
COVID-19 in older people. Nonetheless, guidance relating to the care of older people is emerging 
from the international community.  This guidance spans ethical considerations to the clinical 
management of COVID-19 in different settings [29] with a holistic assessment in their guidance on 
critical care in patients over 65 years old. The French Society of Geriatrics and Gerontology (SFGG) 
have highlighted the non-specific presentation of COVID-19 illness in older people. A joint consensus 
has been collated between the British Geriatrics Society, European Delirium Association, and the 
Faculty of Old Age Psychiatry at the Royal College of Psychiatrists on managing delirium in suspected 
and confirmed cases [18]. Specific guidelines from the United States have been published for 
Emergency Department providers [30] usefully outlining that immunosuppression in older adults, 
and or the presence of comorbidities, should prompt a lower threshold for COVID-19 testing.  In 
addition, this guidance highlights the additional challenge of communicating with people with 
cognitive and sensory impairments whilst personal protective equipment (PPE) is being worn.   
Systematic review methods 
We searched PubMed and bioRxiv/medRxiv to identify all papers describing testing (including 
reverse transciption polymerase chain reaction assays/serology/radiology), treatment (including 
vaccines, at clinical phase only) or prognosis (predictors of clinical or viral outcomes) of COVID-19 
(Figure 1). The search strategy for both databases is presented in Supplementary Data 1. The 
PubMed search was run on 20th March 2020 and the bioRxiv/medRxiv search completed on 24th 
March 2020. Only articles published in English were considered for the purposes of the review. 
Further articles were identified through knowledge of the author team, reference and citation lists, 
and from any systematic reviews identified. Each article was screened by either FEL or ET on the 
basis of the title and abstract. Small workgroups focussing on testing, treatment and prognosis 
examined the full text articles within these topic areas and determined which studies provided 
relevant evidence. Any uncertainty about inclusion was resolved by discussion. Articles identified by 
this electronic search were combined with key clinical practice guidelines from expert groups and 
with relevant grey literature. 
 
 
Testing 
We included a total of 22 studies relating to testing: nineteen cohort studies of reverse-transcription 
polymerase chain reactions (RT-PCR) (9), serological testing (5) and combination testing (5) and 
three cross-sectional studies. Studies of the development and optimisation of current and novel 
laboratory techniques were excluded given the clinical focus of this review.  
PCR 
The World Health Organisation recommend testing of all suspected cases for COVID-19 (Box 1) [31]. 
The gold standard is RT-PCR to detect COVID-19 ribonucleic acid (RNA). The World Health 
Organisation recommend testing of all suspected cases (Figure 1) for COVID-19 [31]. The gold 
standard is RT-PCR to detect COVID-19 ribonucleic acid (RNA). Specimens can be upper respiratory 
(nasopharyngeal or oropharyngeal swab) or lower respiratory (sputum or endotracheal aspirate or 
broncho-alveolar lavage), although viral RNA has been detected in blood, anal swabs [32], stool [33-
35], urine [36, 37] and in the conjunctival sac [38].  
RT-PCR has good sensitivity (95%) and specificity (100%) at low numbers of COVID-19 RNA copies 
and against 297 samples of human respiratory and endemic human coronaviruses [39]. However, 
when applied clinically, a negative covid-19 PCR test may not be sufficient to rule out infection in 
suspected cases. There is discordance between negative respiratory swabs with detected viraemias, 
sputum samples  and broncho-alveolar lavage [40, 41]. Initial PCR-negative suspected patients have 
subsequently become positive on repeat testing [42-45]. Poor specimen quality, specimens collected 
in very early or late disease or sample handling issues may explain these false negative results, and 
in clinical practice RT-PCR sensitivity is reported to be 60-70% [45, 46]. Therefore, a negative result 
in a suspected case does not rule out COVID-19 infection [31], and repeat testing may be advisable. 
The cohort and cross-sectional studies describing the sensitivity of PCR defined suspected cases as 
those presenting with fever, respiratory presentations, imaging findings consistent with COVID-19 or 
case contact [33, 34, 47].  The sensitivity of RT-PCR for diagnosing COVID-19 following alternative 
presentations in older people e.g. delirium or fall, is unknown. None of the studies commented on 
whether sensitivity of RT-PCR was affected by age and with the exception of one cohort study [41], 
the populations involved were younger hospitalised patients. The sensitivity of RT-PCR in older 
patients being cared for in different environments is unknown. 
Understanding viral load dynamics throughout the COVID-19 disease course is important for 
interpreting RT-PCR results. PCR detects a higher viral load [33] and is more likely to be positive in 
earlier phases of the disease [48]. Although PCR tests become negative after viral clearance [19], the 
 
 
time frame of this remains unclear and positive RT-PCR has been shown to persist beyond symptom 
resolution [19, 48]. One study described 7 patients who were discharged following 2 negative RT-
PCR tests, but after 2 weeks follow up had positive results [50]. There remains controversy as to 
whether persistent positive RT-PCR detection of COVID-19 after symptom resolution represents 
ongoing infectivity. Woelfel et al readily isolated live virus from respiratory samples taken in the first 
week of symptoms but were not able to isolate live virus after 8 days despite detecting ongoing high 
viral RNA loads [49].  
Serological testing 
Serological tests of the immunological response to COVID-19 have also been developed and have 
demonstrated positive IgM and IgG in PCR-negative patients.  This could represent better sensitivity 
than PCR, or lower specificity of serology [47, 50]. The utility of serological analysis as a diagnostic 
test for COVID-19 depends on the dynamics of the immunological response. Several large population 
studies have shown low sensitivity of serology in the first 5-7 days of the illness, with this increasing 
steadily as the disease progresses up to positive results of 90-100% between 12 and 20 days since 
following symptom onset [40, 43, 51, 52]. Although one study examined the use of serological 
testing in an outpatient setting in younger patients [54], there are currently no studies examining 
the sensitivity or dynamics of serological testing for COVID-19 in older populations in hospital or 
community settings. 
Other testing 
Characteristic radiological images have also been considered as diagnostic tools for COVID-19 given 
the lack of sensitivity of PCR and serological tests in early disease [53]. However, CT sensitivity is  
also dependent on the time course of symptoms. One study of hospitalised patients with a mean age 
of 51, found 97% positive CT chest findings in 1014 RT-PCR-positive COVID-19 patients, but also 75% 
positive CT chest findings in RT-PCR negative patients. The study reported a sensitivity of 97% with 
68% accuracy and 25% specificity. Furthermore, they found that in a subgroup who tested negative 
and then positive with serial (repeated) RT-PCR, a large proportion (67%, 10/15) had positive initial 
chest CT although this only accounted for only 15.6% of those presenting with typical CT features at 
the time of the initial negative RT-PCR [45]. A retrospective study of 64 COVID-19 PCR-positive 
patients with a mean age of 56 in Hong Kong, showed that 69% of patients had CXR changes at 
presentation. They compared CXR at presentation with RT-PCR disease confirmation on serial 
testing. Presentation CXR changes had a sensitivity for detecting COVID-19 of 69% compared to 91% 
for presentation RT-PCR [53]. Multi-parameter screening tools are now being developed, which 
 
 
consider epidemiological factors, clinical features, radiological findings, and biochemical markers to 
predict a diagnosis of COVID-19 [56].  No study has reported the diagnostic or prognostic role of 
imaging (CXR or CT) independent of the clinical parameters and/or biochemical parameters.  
Rapid and accurate diagnosis of COVID-19 remains important to facilitate case isolation and, in older 
people, prognostication and advance care planning. The sensitivity of testing is dependent on 
disease stage, specimen site and quality. The clinical utility is further limited by test availability and 
delays in receiving results. In a health service faced with a rapidly increasing case load of patients 
with COVID-19, information from these different testing modalities can be incorporated to support 
diagnosis. We stongly advocate adopting a low threshold for testing older people with atypical 
symptoms where the result would alter management at an individual or population level. We 
recognise the lack of specific evidence on sensitivity of diagnostic tools in older  people, testing in 
different care settings, and with varying symptom constellations e.g. dominance of lower or upper 
respiratory tract symptoms, as well as in those who are asymptomatic and / or contacts of positive 
cases.  
Treatments  
We identified two management guidelines [55, 56], four completed small-scale exploratory trials 
[57-60], four case series [12, 61-63], three retrospective reviews [64-66], and one rapid review of the 
effectiveness of antivirals [69]. Of the four trials, three reported experience with antivirals [58-60] 
and one with convalescent plasma [57]. The four case series reported experience with combination 
antivirals, corticosteroids, immunoglobulins and traditional Chinese medicine [12, 61-63]. Two of the 
retrospective reviews reported on the use of corticosteroids [64, 65] while one compared the 
treatment of older (>65 years) and younger patients. In addition, we were already aware of three 
rapid guidelines produced by NICE which covered critical care, dialysis and systemic anticancer 
treatment [NICE guidelines 159-161], [70-72] two WHO guidelines relating to the clinical care of 
people with COVID-19 infection and the Chinese COVID-19 guidance version 7 [71-73]. Since the 
search was completed further guidance on managing COVID-19 in care home settings has been 
produced and disseminated [76]. 
Antivirals 
Gautret and colleagues conducted an open label non-randomised trial in France with 46 people 
(mean age 45 years, SD 22, (three >75 years)) using hydroxychloroquine and azithromycin and 
reported reduced viral loads at day 6 within the treatment group [61]. However, significant concerns 
have been raised about the methodological approach including the lack of control group and analysis 
 
 
whereby the results are likely to be confounded [77]. Chen and colleagues conducted an open label 
randomised superiority trial in China comparing the efficacy of favipiravir and arbidol in 240 people 
(median age 46 years, IQR 34-59 (70 > 65 years)) with confirmed COVID-19 pneumonia [62]. At seven 
days, clinical recovery was higher in those on favipiravir but side effects of abnormal LFTs, 
psychiatric symptoms and GI upset were also more frequently reported [62]. Li and colleagues 
conducted an exploratory randomised controlled trial of lopinavir/ritonavir versus arbidol versus no 
antiviral medication in China in 44 people (mean age 52, SD 15 years, proportion >75 years not 
stated) with moderate COVID-19, and found no clear benefit and some potential harm of 
lopinavir/ritonavir [60].   
Convalescent plasma 
Duan and colleagues reported the feasibility of using pooled convalescent plasma on 10 people 
(median age 53 IQR 45-60, (one>75 years without comorbidity)) with severe COVID-19 already on 
maximal therapy [57]. Viral load became undetectable in 7 out of 10 patients following the infusion. 
No adverse events were reported. The authors felt the intervention was feasible and merited further 
study [57]. 
Corticosteroids 
Wang and colleagues reported reduction in fever and improved oxygen saturations in a 
retrospective review of 46 people (median age 54 IQR 48-64) with severe COVID-19 pneumonia 
given methylprednisolone [67]. Zhou and colleagues reported findings from a retrospective review 
of the outcomes of 10 hospitalised people (mean age 52, SD 15) who received low dose 
corticosteroids and immunoglobulins with the majority also receiving anti-virals and antibiotics. A 
subsequent short course of methylprednisolone and further immunoglobulins were given when their 
condition deteriorated with observed improvement in oxygen requirements and inflammatory 
markers (CRP)[66].  
Combination interventions 
The four case series described the treatment and outcomes of 654 people (median ages 56, IQR 42-
68; 55, IQR 39-67; 46, IQR 34-59; and 48, IQR 29-63) in China with confirmed COVID-19 infection.  
609 (93%) participants received an antiviral including lopinavir/ritonavir (225 (34%)), arbidol (54 
(8%)), oseltamavir (125 (19%)), and interferon (132 (20%). 244 (37%) received steroids. Use of the 
different antivirals or steroids did not appear to be associated with any change in outcome.   Zhang 
and colleagues, however, reported a significantly higher positive fluid balance in those that died on 
 
 
ICU compared with those that were stepped down to wards. This finding has fed into clinical 
guidance on using a cautious intravenous fluid strategy in those with confirmed or suspected COVID-
19 [47]. 
The current evidence for the effectiveness of antiviral, corticosteroid and immunotherapies is 
inconclusive, and previous experience from the treatment of other viral pneumonias points to the 
risk of potentially significant side effects. This is particularly the case for corticosteroids where 
experience from RSV, influenza, and MERS-CoV shows no clear benefit while observational data 
point towards increased mortality and secondary infection rates [58]. On this basis, current guidance 
advocates using corticosteroids only to treat co-existing disease e.g. chronic obstructive pulmonary 
disease (COPD) and sepsis rather than COVID-19 infection / complications. The timings of therapy 
may be important such that anti-virals are utilised to reduce the viral load in early disease with 
corticosteroids or anti-inflammatory therapies having a role in reducing immunopathological 
damage that contributes to mortality as the disease progresses.  
Limited data on the use of antivirals and corticosteroids in older age groups have been published. 
We identified one retrospective review which compared the treatments and escalation 
requirements of 136 older, defined as >60 years, (mean age 68, SD 7) and 652 younger (mean age 
41, SD 11) patients with COVID-19 infections [66]. The older group were more likely to have a severe 
infection (24% vs 7% P<0.001), were more likely to need ICU admission (10% vs 1% P<0.001) and 
were more likely to require mechanical ventilation (7% vs 1% p=0.001). The difference in the 
proportions that received antiviral medications (86% vs 84% p=0.622) may have occurred by chance 
but corticosteroids were given more often in the older group (27% vs 9% p<0.001) reflecting their 
disease severity. More older people remained in hospital at the end of the review period than 
younger people (23% vs 45% p<0.001) [66].  Despite the urgency to identify effective treatments for 
COVID-19 it is imperative that this does not undermine the necessary rigor of therapy evaluation, 
and it is with some concern that we note the reports of the inclusion of unproven antiviral agents in 
national guidelines for the treatment of COVID-19 [78]. Of note, the majority of the studies 
identified in this review predominantly included younger people. Their applicability to older people, 
and populations in countries and healthcare systems outside China is therefore unclear. Future 
studies must prioritise the inclusion of older people to ensure that any findings are valid in the 
population most at risk of negative outcomes.  
 
 
Prognosis   
We identified 13 retrospective cohort studies of patients with COVID-19 that looked at prognosis. 
These studies examined the prognostic ability of one or more baseline factors to predict subsequent 
COVID-19-related outcomes such as death, progression of disease severity, discharge from hospital 
or viral clearance studies (see Table 1, and Table 2 in Supplementary material). Information on such 
factors should help direct the most effective treatment to those for whom it has the potential to 
offer meaningful benefit.  Eleven of the studies used traditional statistical epidemiology methods 
such as Cox regression and logistic regression, while two employed machine learning. Eight of the 
studies examined prognosis according to age. Not surprisingly, they all found that older patients had 
a worse prognosis: one large study observed the death rate to be more than double in the over 65s 
(hazard ratio 2.43, 95% confidence interval 1.66 to 3.56) [4]. Five studies reported prognosis by 
gender and all observed males to have a worse prognosis than females. Several specific 
comorbidities have been reported to predict poorer outcomes, including body mass index (BMI), 
hypertension, diabetes, COPD, coronary heart disease and malignant tumours. Furthermore, 
patients with two or more comorbidities have a poorer prognosis than patients with one [8]. 
Several symptoms were observed to predict outcomes. Higher levels of fever and higher respiratory 
rate in particular are associated with increased rates of progression or mortality, findings that have 
been replicated within or across studies. Numerous laboratory findings have also been observed to 
be prognostic, with higher white blood cell counts, lower lymphocyte counts, higher creatinine, 
higher creatine kinase, higher C-reactive protein, lower albumin, higher IL-6, higher myoglobin, 
higher lactate dehydrogenase, higher procalcitonin, higher high-sensitivity cardiac troponin I, higher 
total bilirubin, higher urea and presence of acute kidney injury, being characteristics consistently 
associated with worse prognosis across two or more studies. Future analysis of sequential 
measurements should help determine the trajectory of change and whether elevated levels in early 
disease are indicative of later deterioration.  
The two studies using machine learning each identified a specific set of predictors. Bai et al identified 
age >55 years, hypertension, decreased albumin, decreased lymphocyte count, progressive 
consolidation on CT scan, elevated CRP and lack of fibrosis at initial CT scan as associated with higher 
risk of progression to severe COVID-19 [79] [80] Yan et al identified higher lactic dehydrogenase, 
lower lymphocytes and higher high-sensitivity CRP as associated with greater risk of mortality from a 
pool of more than 300 features [81]. 
 
 
Broader considerations   
Supportive care 
NICE recommend that the Clinical Frailty Scale (CFS) should be used to provide a functional 
evaluation of people presenting with COVID-19 in those aged 65 and over without long-term 
disability such as cerebral palsy, learning disability or autism.  They advise that in patients with a CFS 
between 1 to 4, who would like to be treated intensively, critical care referral would be appropriate 
[70]. Advanced care planning for those living with frailty, including sensitive consideration about the 
potential benefits of admission to hospital, is recommended. This is particularly relevant to people 
resident in care homes or with high clinical frailty scores where advanced care plans should be 
proactively revisited in the light of the current outbreak [76].  
Guidelines advocate stratifying people by disease severity although older people, and those with 
comorbidity, despite presenting with mild symptoms are at higher risk of severe COVID-19 and of 
unpredictable, rapid, deterioration [73]. Features suggestive of severe COVID-19 include: respiratory 
rate >30 or oxygen saturations <93% on air [75] or CURB65 >1 and should prompt consideration of 
hospital admission [57]. However, the majority of prediction studies examining risk of 
hospitalisation, diagnosis of COVID-19 in those with symptoms and prognosis have been based on 
data from China.  All have had a high risk of bias such that the prediction performance of tools in 
clinical practice is likely to be lower than initially reported [80].     
In the absence of proven treatments for COVID-19, current management is essentially supportive. 
Older people living with frailty (clinical frailty score of 5 or more) presenting with COVID-19 should 
be managed through a comprehensive geriatric medicine framework with multidisciplinary working 
and a patient centred, goal driven approach [73]. Supplemental oxygen should be given to maintain 
oxygen saturations, and electrolyte and coagulation disturbances should be rectified.  Where there is 
established bacterial infection or sepsis [73] or in mechanically ventilated patients [81] antibiotic 
therapy should be used. However, careful antibiotic stewardship is warranted and the diagnosis and 
management should be reviewed at 48-72 hours [84] given the established risk of antibiotic 
resistance, risk of drug toxicity and drug interactions. Use of antibacterials such as azithromycin with 
putative anti-inflammatory or antiviral activity should be given within the context of established 
randomised clinical trials. One such trial is the UK based RECOVERY trial which recently replaced the 
interferon beta arm with azithromycin 500mg for 10 days [85]. Co-morbidities should be managed as 
standard, being mindful of the non-specific presentation of disease in older patients to avoid 
attributing presenting symptoms solely to probable COVID-19 infection. Early medication review 
 
 
should occur to reduce the risks associated with polypharmacy in the context of COVID infection 
[73].  Early, sensitive, discussion around ceilings of care for older frailer people with COVID-19 should 
be carried out.  
Non-pharmaceutical interventions: Social distancing and community containment 
Comprehensive review of all non-drug interventions for COVID-19 infection were beyond the scope 
of this review. Recognising, however, that social distancing has a significant impact on older people 
we conducted a supplementary search to specifically consider the potential negative consequences 
of social distancing in older adults, using terms such as social distancing, social isolation, older adults 
and elderly.   
In the current absence of preventative pharmaceutical interventions, such as vaccines and anti-
virals, classic public health measures are required to reduce and prevent person-to-person 
transmission, namely: isolation and quarantine, social distancing and community containment [84]. 
Isolation and quarantine of ill, or possibly ill, individuals can be effective tools for preventing 
onwards transmission if early detection of cases is possible, as successfully implemented during the 
2003 SARS epidemic [84].  Stricter measures of ‘social distancing’ and even more stringent 
‘community containment’ may be deployed if community transmission, without obvious linkages 
between cases, is evident [84].  With evidence of widespread community transmission of COVID19, 
community containment (‘lockdown’) and social distancing has already been implemented in several 
countries.  For older adults, the focus is on shielding such individuals from infection, because attack 
rates have been shown to be higher, and the disease more severe, in this age group [87].  Such 
measures, however, are highly disruptive for individuals and may have negative unintended 
consequences.   
There is evidence that socially disconnected and isolated older adults are at increased risk of physical 
and mental health problems including cardiovascular disease, stroke, depression, anxiety, dementia 
and premature death, and as a result can require additional health and social care support [88-92].  
For example, chronic loneliness has been associated with an increased number of doctor visits; in a 
study of 3530 older adults living in the community in the United States Gerst-Emerson et al found an 
increased number of doctor’s visits for people reporting loneliness both in 2008 and 2012 (b=0.075, 
p=0.029), but not for each year alone [89].  There was limited evidence for an association with 
hospitalisations; being lonely in 2008 was associated with increased hospitalisations (b= 0.218, 
p=0.031), but not in 2012 or in both years.  Low contact with friends in older adults, exclusion from 
social relationships and subjective feelings of exclusion have been negatively associated with well-
 
 
being and associated with poor self-reported health [93, 94].  Loneliness caused by social isolation 
has been associated with impaired cognitive function in older adults.  In a study of 7,410 Chinese 
older adults, Yang et al found an indirect effect of loneliness and cognitive function (b=−0.17, p<0.05), 
and after controlling for loneliness a direct effect of social isolation on cognitive functioning (b=−0.36, 
p<0.05) [95]. Those experiencing a high degree of loneliness have been found to be at increased risk 
of becoming physically frail.  Gale et al investigated the association between loneliness and pre-
frailty and frailty in 2,346 English older adults and found multivariable adjusted relative risk ratios of 
1.74 (95% CI 1.29, 2.34) for those living with pre-frailty and 1.85 (95% CI 1.14, 2.99) frailty among 
those with a high score for loneliness [96].  The same study considered social isolation and frailty, 
but found no evidence of association in the multivariable model aRRR 1.19 (CI 0.93, 1.53) and 1.12 
(0.70, 1.78) for pre-frailty and frailty respectively) [96].  These data relate to social disconnection, 
isolation and loneliness more generally, as opposed to specifically in relation to social distancing in 
response to COVID-19 or other pandemics; therefore self-isolation during pandemics may result in 
different physical and psychosocial consequences from loneliness at other times.   However, 
this evidence suggests the current social distancing policies could have important negative 
consequences, particularly if in place for an extended period.  
Current and planned trials  
Larger scale trials relating to COVID-19 are a priority and are now underway including the multi-arm 
trials SOLIDARITY run by the WHO [97] and Randomised Evaluation of COVID-19 Therapy 
(RECOVERY) [98]. These will examine some of the drugs identified as promising in early studies 
(lopinavir and ritonavir, chloroquine and hydroxychloroquine) and interferon-beta or 
dexamethasone. There are numerous planned and current clinical trials of adjuvant therapies aimed 
at improving survival in COVID-19.  
As of the 16th March 2020 the WHO International Clinical Trials Registry Platform [99] listed 523 
trials related to COVID-19, of which 258 were therapeutic interventional studies (excluding studies 
on prevention of COVID-19, and rehabilitation in survivors) (12). The majority of these trials are led 
by groups based in China and the United States. The trials can be broadly grouped into the 
aforementioned categories of antiviral (33), antibiotics (0), corticosteroids (4), immunoglobulin (15), 
other (199) or multi-arm combinations (7). The category ‘other’ was varied in terms of trialled drugs, 
including chloroquine (ChiCTR2000029868), interferon (ChiCTR2000030480), herbal compounds 
(ChiCTR2000030545), cytokines (ChiCTR2000030167), stem cell therapies (ChiCTR2000030138) and 
biologic agents (ChiCTR2000029765). In the majority of studies, the primary outcome is all-cause 
mortality, but others measured outcomes include improvement in oxygen saturation 
 
 
(ChiCTR2000029990) or time to fever reduction (ChiCTR2000029781). Notably, 10% of studies 
exclude patients over the age of 65.  This figure rises to 17.4% excluding over-70s, and 37.2% 
excluding over-75s. Given the apparent increased risk of negative health outcomes in older people, it 
is important that this vulnerable group is included in intervention trials with consideration given to 
age-related physiological, pharmacokinetic, pharmacodynamic changes and concurrent comorbidity.  
Discussion and future directions 
The emergence of COVID-19 represents a dynamic, specific and real threat to the health and well-
being of older people. The scope of COVID-19 is such that ethical support is being proposed to aid in 
the decisions on critical care [98, 99], and the rapid NICE guidelines [70] suggest the use of the CFS in 
triage. These aspects combined with the compelling evidence that advanced age is a prognostic 
indicator for poorer outcome provides a clear basis on which guidance on the management of 
COVID-19 in older people is warranted [100, 101]. The research field is rapidly evolving as 
understanding of the clinical characteristics, transmission, and necessary public health and 
interventional measures becomes clearer. Recognising the real need for clinicians on the front lines 
to have reliable information, we have sought to rapidly synthesise and summarise the current 
evidence base of testing, treatments and prognostic factors, in addition to detailing the clinical and 
radiological features of the disease.  Finally, we have provided a synopsis of the field of prospective 
clinical trials, with specific reference to the age-specific inclusion criteria.  
One of the strengths of this paper has been the rapid screening of more than 1000 articles.  In 
addition to the standard inclusion of published peer reviewed papers, the addition of pre-print 
articles is a particular strength that provides greater contemporary insight. We have set this 
literature review in the context of what is currently known about the clinical and radiological 
features of the disease, and we have systematically identified and summarised papers relating to 
prognosis.   We anticipate that this may inform clinical practice in targeting treatment strategies 
accordingly.   The limitations of this review include the fact that we have only identified papers 
published in English and have excluded editorials, correspondence, commentaries and single case 
reports.  Evidence that has not been peer reviewed should be considered within that context and 
the findings interpreted with caution. Furthermore, the reported results may be subject to reporting 
biases, and particularly to selective presentation of findings in the investigations of prognosis.  The 
degree to which prognostic data from China is more widely generalisable is unknown and these data 
are not specific for older adults.  
 
 
Future research     
Our review has highlighted areas with a paucity of evidence that may be tackled with future research 
(Box 4). This is a core component of the Department of Health and Social Care COVID-19 strategy to 
Contain; Delay; Research; and Mitigate. These research objectives align with the approaches 
advocated by organisations including the BGS [104]. 
Testing  
More research is needed to establish the sensitivity of diagnostic testing in older people, who are 
largely omitted from existing cohort studies of sensitivity. This further work should examine 
sensitivity in those with non-specific presentations and within different care settings e.g. care homes 
or patients own homes.  Additionally, understanding of the dynamics of RT-PCR and serological 
testing throughout the COVID-19 disease course to guide interpretation of diagnostic tests will be 
valuable.  Indications for testing patients in care homes to include non-specific presentation of 
COVID-19 illness would potentially facilitate containment and appropriate treatment  
Presentation  
Areas of focus may include evaluation of atypical and non-specific presentation of COVID-19 in older 
people, specific prognostic factors for those treated outside of intensive care settings, the impact of 
cognitive impairment and delirium on management, considerations about providing care in 
community settings, including nursing and residential homes, as well as optimal care for patients at 
the end of their lives. 
Treatment and rehabilitation  
We strongly advocate that upper age limits in interventional trials are justified, and that awareness, 
access and participation of older people in clinical trials is facilitated. Exclusion of older people, 
particularly those with comorbidities, from clinical trials is well recognised. Findings from trials that 
have enrolled younger participants are often extrapolated and applied in the management of older 
adults; a heterogeneous group of individuals. We have demonstrated a very real risk of ‘ageism’ 
occurring in the current portfolio of COVID-19 interventional trials whereby almost 40% of studies 
plan to exclude people over the age of 75. We are encouraged that this is not a feature of some of 
the larger trials including the 5 arm, SOLIDARITY trial [105] led by the WHO which includes a 
remdesivir treatment arm supporting promising in vitro findings. The 5 arm, UK RECOVERY trial [85], 
the 3 domain REMAP-CAP trial [106] all use adaptive design to tackle multiple hypotheses, providing 
rapid evidence on which to base care.   
 
 
Development and evaluation of effective rehabilitation strategies and trajectories will be required 
for older people who have either experienced severe or critical COVID-19 infection and / or have 
mild or moderate disease but are living with frailty or comorbidity. The NHS Discharge to Assess 
model anticipates that 45% of patients will require support from health and social care on discharge 
from hospital with a further 4% requiring a bedded setting.[107]  Identification of rehabilitation 
settings to prevent the long-term adverse effects of COVID-19 may require specialist facilities or at 
least additional capacity to relieve pressure on acute services [108]. Data from survivors of acute 
respiratory distress syndrome (ARDS) and severe influenza A (H1N1) whom have been managed in 
intensive care settings suggests that the cognitive dysfunction and negative psychological sequalae 
including post-traumatic stress disorder, anxiety and depression in patients and families are 
common and should therefore provide a focus for intervention and evaluation.[109]    
We wholly support the public health measures that support reduction in COVID-19 transmission. 
Effectiveness of future public health interventions such as vaccination, shielding and potential 
prophylactic treatments should include robust evaluation of unintended but potentially inevitable 
negative sequalae.  Social distancing and isolation offer both protection and risk to some of the most 
vulnerable individuals in society. Future focus on aspects such as loneliness, deconditioning, 
progression of frailty and neglect of comorbidities are warranted as well as measures that might 
mitigate these harms.     
 
Conclusion  
The COVID-19 pandemic presents emergent and novel challenges as it evolves. Our review has 
highlighted areas within the domains of testing, treatment and prognostication that warrant future 
study. It will be imperative that research is proactively inclusive of older people so as to optimise 
prevention, treatment and rehabilitation strategies in this at-risk group.     
 
 
  
 
 
 
Box 1 World Health Organisation suspected case definition ([5]) 
A suspected case is: 
 A. a patient with acute respiratory illness (that is, fever and at least one sign or symptom of 
respiratory disease, for example, cough or shortness of breath) AND with no other aetiology that 
fully explains the clinical presentation AND a history of travel to or residence in a country, area or 
territory that has reported local transmission of COVID-19 disease during the 14 days prior to 
symptom onset  
 
OR 
 
 B. a patient with any acute respiratory illness AND who has been a contact of a confirmed or 
probable case of COVID-19 disease during the 14 days prior to the onset of symptoms (see the 
definition of contact below) 
 
 OR  
 
 C. a patient with severe acute respiratory infection (that is, fever and at least one sign or 
symptom of respiratory disease, for example, cough or shortness breath) AND who requires 
hospitalization AND who has no other aetiology that fully explains the clinical presentation. 
  
  
 
 
Box 2.  Clinical Overview of COVID-19 
Clinical Manifestations 
• Fever [7] 
• Dry Cough [7] 
• Dyspnoea 
• Myalgia 
• Fatigue 
• Diarrhoea [17] 
• Asymptomatic [110] 
• Acute Respiratory Distress Syndrome [7, 17] 
• Atypical presentations (e.g. behavioural change, balance problems, falls), particularly in 
older adults  
• Anosmia [9]  
 
Typical biochemical Findings (not exhaustive) [17, 19]  
• Lymphopenia  
• Elevated C-reactive protein 
 
Radiological Findings [24] 
• CXR [22] 
o  bilateral, ground glass opacification which is ill-defined and more commonly seen in 
the periphery and the right-lower lobe 
• CT Chest  
o Can be normal in the early stages of disease, but a normal CT after a week suggests 
COVID-19 much less likely  
o Lower lobe predominant, peripheral predominant, multiple, bilateral foci of ground 
glass opacity  
o ± Crazy-paving, Peripheral consolidation, Air bronchograms, Reverse halo/ 
perilobular pattern 
 
Causes of Death [3, 19]  
• Pneumonia  
• Sepsis (viral or bacterial)  
• Severe Acute Respiratory Syndrome  
  
 
 
Figure 1. Systematic search results   
 
 
 
  
 
 
 
Box 3.  Useful resources  
World Health Organisation 
Case Management: outlines the management of people with COVID-19 infection in secondary care 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-
management 
 
European Geriatric Medicine Society  
EuGMS Task Force on COVID-19 collates topics on care of older people during the coronavirus 
pandemic from across Europe  
 https://www.eugms.org/news/read/article/490.html  
 
The National Institute for Health and Care Excellence 
UK Rapid guidelines and evidence reviews including critical care, patients on dialysis, risk of 
angiotensin converting enzyme (ACE) inhibitors and NSAIDS 
https://www.nice.org.uk/covid-19 
 
UK Government  
Advice on people in residential care and supported living 
https://www.gov.uk/government/publications/covid-19-residential-care-supported-living-and-
home-care-guidance 
 
Ethical framework for planning adult social care during the coronavirus outbreak  
https://www.gov.uk/government/publications/covid-19-ethical-framework-for-adult-social-care 
 
British Geriatrics Society  
COVID-19: Managing the COVID-19 pandemic in care homes: good practice guide [76] 
https://www.bgs.org.uk/resources/covid-19-managing-the-covid-19-pandemic-in-care-homes 
 
Coronavirus: Managing delirium in confirmed and suspected cases [18] 
https://www.bgs.org.uk/resources/coronavirus-managing-delirium-in-confirmed-and-suspected-
cases 
 
British Society of Thoracic Imaging 
COVID-19 guidance for the reporting radiologist 
https://www.bsti.org.uk/standards-clinical-guidelines/clinical-guidelines/bsti-covid-19-guidance-
for-the-reporting-radiologist/ 
 
 
 
 
Table 1 Prognostic Studies – Study characteristics and outcomes  
Reference Sample 
Size 
Population Hospital Admissions Outcome 
Fu L [111] 200 
 
Hospital admissions confirmed by real-time RTPCR 
assay for SARS-CoV-2 RNA 
Union Hospital of Huazhong 
University of Science and 
Technology, Wuhan, China 
1 Jan – 30 Jan 
2020 
 
Mortality 
Gao L [2] 54 Hospital admissions with Laboratory (RT-PCR) 
confirmed SARS-Cov-2 infection; CT of the lung 
conformed to the manifestation of viral pneumonia. 
Hubei General hospital, 
Chongqinq, China 
Not available Mortality 
Liu W [1] 78 Hospital admissions with positive test result for 
COVID-19 nucleic acids by real-time fluorescence 
reverse transcription-polymerase chain reaction 
(RT-PCR)  
hospitalized for > 2 weeks, died while hospitalized, 
or had recovered and been discharged 
1) The Central Hospital of 
Wuhan, 2) Tongji Hospital, 3) 
Wuhan Pulmonary Hospital, 
Wuhan, China 
30 Dec 2019 – 
15 Jan 2020 
Disease progression to severe, critical 
or death 
Zhou F [3] 191 Hospital admissions diagnosed with COVID-19 
according to WHO interim guidance 
Jinyintan Hospital and Wuhan 
pulmonary hospital, Wuhan, 
China 
29 Dec 2019 – 
31 Jan 2020 
Mortality 
Chen J 
[110] 
249 Hospital admission diagnosed according to Chinese 
national guideline for COVID-19 diagnosis and 
treatment, as well as the World Health Organization 
interim guidance 
Shanghai Public Health Clinical 
Center (SPHCC), Shanghai, China 
20 Jan – 6 Feb 
2020 
ICU admission 
Guan W 
[111] 
1590 high-throughput sequencing or real-time reverse-
transcription polymerase-chain-reaction (RT-PCR) 
assay findings for nasal and pharyngeal swab 
specimens were positive 
575 Hospitals across China, 
nationwide 
21 Nov 2019 – 
31 Jan 2020 
ICU admission, or invasive ventilation, 
or death 
 
Liu J [80] 64 Medical staff following admission to isolation wards 
with RT-PCR positive nCoV-19 positive cf. WHO 
interim guidance 
Wuhan Union Hospital, Wuhan, 
China 
16 Jan – 15 
Feb 2020 
Hospital discharge 
Cai Q [114] 298 Hospital admissions confirmed according to WHO 
interim guidance (RT-PCR) 
Third people's Hospital of 
Shenzhen, Guangdong, China 
11 Jan – 6 Feb 
2020 
Duration of positive viral test results. 
Virus clearance defined as 2 negative 
qPCR detection results at an interval 
of 24h 
  
 
 
Reference Sample 
Size 
Population Hospital Admissions Outcome 
Cheng Y 
[115] 
701 (of 
which 
442 
included 
in 
prognost
ic 
analysis) 
Hospital admissions COVID-19–positive according 
to the guidance provided by the Chinese National 
Health Commission: ≥2 clinical diagnosis criteria 
and a positive result to high-throughput 
sequencing or RT-PCR assay. 
Patients with a history of maintenance dialysis or 
renal transplantation were also excluded  
Tongji Hospital, Wuhan, China 28 Jan -11 Feb 
2020 
Mortality 
association between kidney disease 
and in-hospital death 
 
Yang P 
[116] 
55 Hospital admission with SARS-CoV-2 confirmed by 
qRT-PCR or sequencing 
Fifth Medical Center of PLA 
General Hospital, Beijing, China 
27 Dec 2019 – 
18 Feb 2020 
Disease progression 
Liu R [117] 41 Staff of the central hospital of Wuhan admitted 
with COVID-19 confirmed by RT-PCR 
Central Hospital of Wuhan, 
Wuhan, China 
15 Jan – 24 Jan 
2020 
In-hospital adverse events (defined 
as respiratory failure or ARDS, 
transfer to ICU, invasive mechanic 
ventilation, acute cardiac injury, 
acute kidney injury, acute hepatic 
injury, acute myocyte injury, shock, 
secondary infection and death) 
Bai X [79] 199 Hospital admission with positive viral nucleic acid 
test result on throat swab samples (n=80) or 
clinical parameters (n=53)  
Wuhan Pulmonary Hospital, 
Wuhan, China 
3 Jan – 13 Feb 
2020 
 
Progression of disease severity (using 
machine learning; results not in 
Appendix 2 Table 2) 
Yan L  [81] 404 Hospital admissions with SARS-CoV-2 nucleic acid 
positive by RT-PCR; or 2) virus shares detected by 
high homology with the known sequence of SARS-
CoV-2 in respiratory or blood samples 
Tongji Hospital, Wuhan, China. 
 
10 Jan – 18 Feb 
2020 
 
Critical illness (using machine 
learning with supervised XGBoost 
classifier, results not in Appendix 2 
Table 2) 
 
 
 
 
Box 4.  Suggested future research directions 
Testing 
 
Identification of the diagnostic accuracy, indication and optimal method(s) for testing in older 
people in the presence and absence of symptoms and in different settings e.g. primary versus 
secondary care, residential and nursing homes.  
 
Clinical presentation  
 
Evaluation of the extent to which frailty, comorbidity, and age and specific drugs (e.g. ACE inhibitors, 
non-steroidal anti-inflammatories (NSAIDs) and others e.g. immunosuppressants) influence the 
clinical presentation and disease trajectory of COVID-19 in older people. Ascertainment of the 
longer-term morbidity with evaluation of physical, cognitive and psychosocial outcomes.   
 
Treatment and rehabilitation    
 
Ongoing monitoring and advocacy to ensure that randomised clinical trials recruit older adults and 
that their enrolment is facilitated.  Rapid implementation and evaluation of established and novel 
rehabilitation strategies are required to support post-acute care of older patients with COVID-19 
infection. Evaluation of the advanced care planning discussion, documentation and communication 
along with optimal treatment strategies at the end of life.   
 
Wider impact 
 
Ascertainment of the impact of public health measures, particularly social isolation, on older people 
is warranted to determine the relative risks versus benefit of these strategies. Evaluation of 
multidisciplinary working across organisations to optimise acute care and rehabilitation.      
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